ASX:PAR Revenue

Paradigm Biopharmaceuticals had revenue of -25.15K AUD in the half year ending June 30, 2026.

Revenue

n/a

Revenue Growth

n/a

P/S Ratio

n/a

Revenue / Employee

n/a

Employees

n/a

Market Cap

170.77M

Revenue Chart

Chart

Revenue History

Fiscal Year End	Revenue	Change	Growth
Jun 30, 2026	-	-	-
Jun 30, 2025	-	-	-
Jun 30, 2024	-	-	-
Jun 30, 2023	-	-	-
Jun 30, 2022	79.22K	58.67K	285.52%
Jun 30, 2021	Upgrade Pro	Upgrade Pro	Upgrade Pro
Jun 30, 2020	Upgrade Pro	Upgrade Pro	Upgrade Pro
Jun 30, 2019	Upgrade Pro	Upgrade Pro	Upgrade Pro
Jun 30, 2018	Upgrade Pro	Upgrade Pro	Upgrade Pro
Jun 30, 2017	Upgrade Pro	Upgrade Pro	Upgrade Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Related Stocks

Company Name	Revenue
BLS Pharmaceuticals	73.91M
Actinogen Medical	12.67M
Orthocell	11.41M
Recce Pharmaceuticals	9.47M
Dimerix	6.35M
Alterity Therapeutics	3.61M
Arovella Therapeutics	3.50M
Nyrada	2.01M

Revenue Rankings

Paradigm Biopharmaceuticals News

3 years ago - Australia's Paradigm Biopharmaceuticals says phase 2 trial in osteoarthritis shows signs of disease modification at 6-month follow-up - GlobeNewsWire
4 years ago - PARADIGM BIOPHARMACEUTICALS LTD. APPOINTS MARCO POLIZZI as CHIEF EXECUTIVE OFFICER - PRNewsWire
4 years ago - PARADIGM BIOPHARMACEUTICALS SPOTLIGHTS POTENTIAL BREAKTHROUGH OSTEOARTHRITIS TREATMENT AT BIOLOGICAL ASSOCIATION 3RD ANNUAL SUMMIT - PRNewsWire
4 years ago - Paradigm Biopharmaceuticals Retains Rubenstein Public Relations as Agency of Record - PRNewsWire
4 years ago - FDA Grants Fast Track Designation for Paradigm Biopharmaceuticals Phase III Osteoarthritis Program - PRNewsWire
4 years ago - Paradigm Biopharmaceuticals Initiates a Phase 3 Clinical Trial in Knee Osteoarthritis Across the U.S - PRNewsWire

More News